As of Apr 20, 2018 Coherus Biosciences Inc (NASDAQ:CHRS) Sellers Reduced Their Shorts By 6.95%

April 20, 2018 - By Julia Strobel

Coherus BioSciences, Inc. (NASDAQ:CHRS) Corporate Logo

During Q4 2017 the big money sentiment increased to 1.16. That’s change of 0.09, from 2017Q3’s 1.07. 13 investors sold all, 24 reduced holdings as Coherus BioSciences, Inc. ratio improved. 32 increased positions while 11 funds amassed positions. Funds hold 49.09 million shares thus 5.36% more from 2017Q3’s 46.59 million shares.
Gp One Trading L P reported 16,191 shs. Bank Of New York Mellon reported 0% of its capital in Coherus BioSciences, Inc. (NASDAQ:CHRS). Td Asset Mngmt holds 15,671 shs. Goldman Sachs has invested 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Franklin, California-based fund reported 24,000 shs. Citigroup owns 38,331 shs. 3,400 were accumulated by Great West Life Assurance Company Can. Blackrock holds 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS) or 3.20 million shs. 17,763 were accumulated by State Board Of Administration Of Florida Retirement. Price T Rowe Associate Md reported 919,202 shs. 111,704 were reported by Credit Suisse Ag. Kennedy Cap Mngmt Inc owns 0.02% invested in Coherus BioSciences, Inc. (NASDAQ:CHRS) for 96,784 shs. Dekabank Deutsche Girozentrale holds 22,400 shs or 0% of its capital. Alyeska Inv Grp Inc Limited Partnership invested 0.04% in Coherus BioSciences, Inc. (NASDAQ:CHRS). 389,013 were accumulated by Geode Cap Management Ltd Liability Corporation.

It was reported a decrease on Coherus Biosciences Inc (NASDAQ:CHRS)’s shares shorted with 6.95%. FINRA issued in April CHRS’s total 6.54M shares shorted. Previously was reported down change of 6.95% from 7.02 million shares. Previous CHRS’s position will need 8 days to restore. It has 826,900 average volume. Float short on Coherus Biosciences Inc is 15.7%.

CHRS is touching $11.7 during the last trading session, after decreased 2.90%.Currently Coherus BioSciences, Inc. is downtrending after 49.07% change in last April 20, 2017. CHRS has also 49,062 shares volume. CHRS underperformed by 60.62% the S&P 500.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide.The firm is valued at $703.80 million. The companyÂ’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma.Currently it has negative earnings. The Company’s product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, CrohnÂ’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

Coherus BioSciences, Inc. (NASDAQ:CHRS) Ratings Coverage

In total 2 analysts cover Coherus Biosciences (NASDAQ:CHRS). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. (NASDAQ:CHRS) has 100% bullish analysts. 3 are the (NASDAQ:CHRS)’s ratings reports on Apr 20, 2018 according to StockzIntelligence Inc. On Friday, March 9 the stock of Coherus BioSciences, Inc. (NASDAQ:CHRS) earned “Buy” rating by Citigroup. The company rating was maintained by Maxim Group on Friday, March 9.

Coherus BioSciences, Inc. (NASDAQ:CHRS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.